Oruka Therapeutics
ORKA
26 hedge funds and large institutions have $5.02M invested in Oruka Therapeutics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
24% more funds holding
Funds holding: 21 → 26 (+5)
0.03% less ownership
Funds ownership: 1.49% → 1.46% (-0.03%)
18% less capital invested
Capital invested by funds: $6.09M → $5.02M (-$1.07M)
31% less call options, than puts
Call options by funds: $148K | Put options by funds: $213K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$50.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.3K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$32.9K |
| 4 |
HF
HRT Financial
New York
|
+$31.6K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$332K |
| 2 |
NM
Newtyn Management
New York
|
-$40.7K |
| 3 |
Jane Street
New York
|
-$34.5K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$53 |
ORKA Hedge Fund Activity: Q1 2023 in Review
26 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2023, worth a combined $5.02M — down 18% from $6.09M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ORKA positions and 1 closed out — a net gain of 5 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Group One Trading, opening a new position worth an estimated $50.5K. The largest seller was BML Capital Management, cutting an estimated $332K.
- 26 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2023, up from 21 in Q4 2022.
- Funds reported $5.02M of Oruka Therapeutics stock for Q1 2023, down 18% quarter-over-quarter.
- 6 funds opened new Oruka Therapeutics positions in Q1 2023 and 1 closed out, a net change of +5 holders.
- The largest Oruka Therapeutics buyer in Q1 2023 was Group One Trading, an estimated $50.5K added.
- The largest Oruka Therapeutics seller in Q1 2023 was BML Capital Management, an estimated $332K sold.
Based on aggregated 13F filings for Q1 2023.